Genomic Testing & Current Trends in the Treatment of Non-Small Cell Lung Cancer

Listen Now

Topics Covered

• Overview of Non-Small Cell Lung Cancer, in the Context of COVID-19
• Definition of Genomics & Genomic Testing
• The Difference between Genomics & Genetics
• The Role of Genomic Testing in the Treatment of Non-Small Cell Lung Cancer
• Specific Examples of How Genomic Testing May Inform Treatment Decisions
• Precision Medicine
• Current Research on Genomics
• Liquid Biopsies
• The Role of the Pathologist
• Reviewing Your Pathology Report with Your Pathologist & Health Care Team
• Key Questions to Ask Your Health Care Team about Genomic Testing & Its Benefits for Your Treatment
• Follow-Up Care
• Guidelines to Prepare for Telehealth Appointments with Your Health Care Team, including Technology & Prepared List of Questions
• Questions for Our Panel of Experts

Our Panel of Experts

Bob T. Li, MD, MPH

Medical Oncologist, Thoracic Oncology and Early Drug Development Service, Chief Scientific Officer, MSK Direct, Co-Director, Thoracic Liquid Biopsy Program, Physician Ambassador to China and Asia-Pacific; Bobst International Center; Memorial Sloan Kettering Cancer Center

Joshua K. Sabari, MD

Attending Physician, Thoracic Medical Oncology, Assistant Professor of Medicine, NYU Langone Health, Perlmutter Cancer Center

Katie Brown, OPN-CG

Vice President, Support & Survivorship Programs, LUNGevity Foundation

Carolyn Messner, DSW, BCD, FAPOS, FAOSW

Director of Education and Training, CancerCare

Brochure

You can download the brochure for this workshop

Workshop Date

This workshop was originally recorded on June 22, 2021.